Imaging Lymphoid Cell Death In Vivo During Polymicrobial Sepsis*

Objectives: Cell death in lymphatic organs, such as the spleen, is in part responsible for immunosuppression and contributes to mortality during sepsis. An early and noninvasive detection of lymphoid cell death could thus have significant clinical implications. Here, we tested in vivo imaging of lymphoid cell death using a near-infrared annexin V (AV-750). Design: Animal study. Setting: Laboratory investigation. Subjects: C57BL/6J wild-type and toll-like receptor 3 knockout mice. Interventions: Mild and severe polymicrobial sepsis was induced with cecum ligation and puncture. Serum cytokines and acute kidney injury markers were tested by immunoassay and quantitative reverse transcription-polymerase chain reaction, respectively. Sepsis-induced lymphoid cell death was detected by fluorescent AV-750 accumulation in the thorax and abdomen (in vivo), in isolated organs (ex vivo), and in isolated cells (flow cytometry). Caspase-3 cleavage/activity and terminal deoxynucleotidyl transferase dUTP nick-end labeling staining were tested for apoptosis. Measurements and Main Results: Severe sepsis induced marked apoptosis in the thymus, spleen, and liver as demonstrated by cleaved caspase-3 and an increase in caspase-3 activity and terminal deoxynucleotidyl transferase dUTP nick-end labeling–positive cells. A significant increase in fluorescent AV-750 signal was seen in the thoracic and upper abdominal fields and associated with the severity of sepsis. The in vivo thoracic and abdominal AV-750 fluorescent signal was attributed to the thymus, liver, and spleen as determined by ex vivo imaging and highly correlated with the levels of cell death in thymocytes and splenocytes, respectively, as measured by flow cytometry. Compared with wild-type septic mice, toll-like receptor 3 septic mice had attenuated abdominal AV-750 fluorescent signal, reduced ex vivo fluorescence in the spleen, and decreased splenocyte cell death. Conclusions: In vivo AV-750 fluorescent imaging provides spatially resolved and organ-specific detection of lymphoid cell death during polymicrobial sepsis. The AV-750 fluorescent intensity in the thoracic and abdominal fields is associated with sepsis severity and well correlated with sepsis-induced cell death in the thymus and spleen, respectively.

[1]  L. Josephson,et al.  Cytoprotective nanoparticles by conjugation of a polyhis tagged annexin V to a nanoparticle drug. , 2015, Nanoscale.

[2]  C. Benoist,et al.  Genomic responses to inflammation in mouse models mimic humans: We concur, apples to oranges comparisons won’t do , 2014, Proceedings of the National Academy of Sciences.

[3]  T. Miyakawa,et al.  Reply to Warren et al. and Shay et al.: Commonalities across species do exist and are potentially important , 2014, Proceedings of the National Academy of Sciences.

[4]  I. Cinel,et al.  Sepsis and Acute Kidney Injury. , 2014, Turkish journal of anaesthesiology and reanimation.

[5]  R. Hotchkiss,et al.  Persistent Lymphopenia After Diagnosis of Sepsis Predicts Mortality , 2014, Shock.

[6]  Keizo Takao,et al.  Genomic responses in mouse models greatly mimic human inflammatory diseases , 2014, Proceedings of the National Academy of Sciences.

[7]  J. Thurman,et al.  Complement Factor B Is the Downstream Effector of TLRs and Plays an Important Role in a Mouse Model of Severe Sepsis , 2013, The Journal of Immunology.

[8]  J. Bertin,et al.  Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL* , 2013, The Journal of Biological Chemistry.

[9]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[10]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[11]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[12]  Yan Li,et al.  Nonhematopoietic Toll-Like Receptor 2 Contributes to Neutrophil and Cardiac Function Impairment During Polymicrobial Sepsis , 2011, Shock.

[13]  Yan Li,et al.  Myocardial Ischemia Activates an Injurious Innate Immune Signaling via Cardiac Heat Shock Protein 60 and Toll-like Receptor 4* , 2011, The Journal of Biological Chemistry.

[14]  Shi-Xian Deng,et al.  The Ngal Reporter Mouse Detects the Response of the Kidney to Injury in Real Time , 2010, Nature Medicine.

[15]  P. Devarajan,et al.  Review: Neutrophil gelatinase‐associated lipocalin: A troponin‐like biomarker for human acute kidney injury , 2010, Nephrology.

[16]  M. Scherrer-Crosbie,et al.  Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis* , 2010, Critical care medicine.

[17]  G. Dai,et al.  Molecular MRI Detects Low Levels of Cardiomyocyte Apoptosis in a Transgenic Model of Chronic Heart Failure , 2009, Circulation. Cardiovascular imaging.

[18]  R. Star,et al.  Animal models of sepsis and sepsis-induced kidney injury. , 2009, The Journal of clinical investigation.

[19]  C. Coopersmith,et al.  The sepsis seesaw: tilting toward immunosuppression , 2009, Nature Medicine.

[20]  K. Honda,et al.  A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity , 2008, Proceedings of the National Academy of Sciences.

[21]  Haitao Wen,et al.  TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events , 2008, The Journal of experimental medicine.

[22]  Y. Ni,et al.  Preliminary in vivo evaluation of a novel 99mTc-labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. , 2008, Bioorganic & medicinal chemistry letters.

[23]  C. Chung,et al.  The apoptotic pathway as a therapeutic target in sepsis. , 2007, Current drug targets.

[24]  J. Siddiqui,et al.  Mechanisms of Mortality in Early and Late Sepsis , 2006, Infection and Immunity.

[25]  C. Reutelingsperger,et al.  Past, present, and future of annexin A5: from protein discovery to clinical applications. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  L. Doughty,et al.  In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. , 2005, Blood.

[27]  Ralph Weissleder,et al.  Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto‐optical nanoparticle , 2005, Magnetic resonance in medicine.

[28]  F. Hoebers,et al.  In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  H. Bartelink,et al.  In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. , 2004, International journal of radiation oncology, biology, physics.

[30]  A. Schroit,et al.  Aminophospholipid asymmetry: A matter of life and death. , 2003, Annual review of physiology.

[31]  P. Wischmeyer,et al.  Distance of Cecum Ligated Influences Mortality, Tumor Necrosis Factor-Alpha and Interleukin-6 Expression following Cecal Ligation and Puncture in the Rat , 2003, European Surgical Research.

[32]  I. Chaudry,et al.  Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity , 2003, Journal of leukocyte biology.

[33]  D. Angus,et al.  Unraveling severe sepsis: why did OPTIMIST fail and what's next? , 2003, JAMA.

[34]  P. Thimister,et al.  In vivo detection of cell death in the area at risk in acute myocardial infarction. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[36]  Roland Hustinx,et al.  Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[38]  R. Hotchkiss,et al.  Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.

[39]  C. Reutelingsperger,et al.  Visualisation of cell death , 2000, The Lancet.

[40]  R. Hotchkiss,et al.  Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte , 2000, Nature Immunology.

[41]  P. Doevendans,et al.  Visualisation of cell death in vivo in patients with acute myocardial infarction , 2000, The Lancet.

[42]  S. Korsmeyer,et al.  Prevention of lymphocyte cell death in sepsis improves survival in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Hotchkiss,et al.  Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.

[44]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[45]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[46]  N. Goldstein Mice are not men! , 1994, Hawaii medical journal.

[47]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[48]  R. Flavell,et al.  Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. , 2007, American journal of physiology. Heart and circulatory physiology.

[49]  G.,et al.  Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis , 2000 .

[50]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. , 1998, Lancet.